1. Home
  2. Directory
  3. Connecticut
  4. Bethel
  5. Podiatrist
  6. NPI Profile
  7. Prescriptions 1083000269

JAMIE ANTHONY OTFINOSKI DPM
Prescription History 1083000269
Podiatrist in Bethel, CT


Quality Rating: 94.24 out of 100 score

NPI Status: Active since April 14, 2015

Contact Information

8 SCHOOL ST
BETHEL, CT
ZIP 06801
Phone: (203) 743-7083

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for JAMIE ANTHONY OTFINOSKI DPM, an active Podiatrist specialist practicing in Bethel, CT. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 90 documented patient claims. Among these therapy options, the most frequently utilized medication is Clotrimazole-Betamethasone, which accounts for 33 claims alone.

Medication Index

A
C
J
No matching medications currently found on file.

Amoxicillin-Clavulanate Potass

Generic Formulation: Amoxicillin/Potassium ClavSpecialty: Podiatry
Provider Metrics Summary
Total Claims 31
30-Day Fills 31.0
Days Supply 293
CT State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills22.3
Peer Average Days Supply198
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 40.9% more claims than the standard regional baseline profile for CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $272.23 across this reporting matrix range.

Provider Avg Cost Per Claim

$8.78

State Avg Cost Per Claim

$14.26

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A fixed-ratio combination of amoxicillin trihydrate and potassium clavulanate.

Therapeutic Applications

Amoxicillin/clavulanic acid is a combination penicillin-type antibiotic used to treat a wide variety of bacterial infections. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Cephalexin

Generic Formulation: CephalexinSpecialty: Podiatry
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 82
CT State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills28.2
Peer Average Days Supply283
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 57.7% less volume than the regional standard for practitioners inside CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $256.23 across this reporting matrix range.

Provider Avg Cost Per Claim

$23.29

State Avg Cost Per Claim

$10.62

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semisynthetic cephalosporin antibiotic with antimicrobial activity similar to that of CEPHALORIDINE or CEPHALOTHIN, but somewhat less potent. It is effective against both gram-positive and gram-negative organisms.

Therapeutic Applications

This medication is used to treat a wide variety of bacterial infections. This medication is known as a cephalosporin antibiotic. It works by stopping the growth of bacteria. This medication will not work for viral infections (such as common cold, flu). Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Clotrimazole-Betamethasone

Generic Formulation: Clotrimazole/Betamethasone DipSpecialty: Podiatry
Provider Metrics Summary
Total Claims 33
30-Day Fills 35.0
Days Supply 1,020
CT State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills24.5
Peer Average Days Supply538
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 43.5% more claims than the standard regional baseline profile for CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,252.81 across this reporting matrix range.

Provider Avg Cost Per Claim

$37.96

State Avg Cost Per Claim

$30.40

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This combination medication is used to treat a variety of inflamed fungal skin infections such as ringworm, athlete's foot, and jock itch. This product contains 2 medications. Clotrimazole is an azole antifungal that works by preventing the growth of fungus. Betamethasone is a strong corticosteroid that works by reducing the swelling, redness, and itching that occurs in the skin infection. This medication is not recommended for children younger than 17 years or for diaper rash.

Jublia

Generic Formulation: EfinaconazoleSpecialty: Podiatry
Provider Metrics Summary
Total Claims 15
30-Day Fills 18.4
Days Supply 550
CT State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills20.8
Peer Average Days Supply613
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $16,800.40 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,120.03

State Avg Cost Per Claim

$1,026.57

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat toenail infection caused by fungus. It works by stopping the growth of certain types of fungus. Efinaconazole belongs to a class of drugs known as azole antifungals. This medication treats only fungal infections. It will not work for other types of infection, such as those caused by bacteria. Unnecessary use or overuse of any drug used to treat infection can lead to its decreased effectiveness.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like JAMIE ANTHONY OTFINOSKI DPM provides transparency into local medical care patterns within Bethel, CT.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Podiatrist** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.